Search

Your search keyword '"van Duin Mark"' showing total 257 results

Search Constraints

Start Over You searched for: Author "van Duin Mark" Remove constraint Author: "van Duin Mark"
257 results on '"van Duin Mark"'

Search Results

1. An IL-1β-driven neutrophil–stromal cell axis fosters a BAFF-rich protumor microenvironment in individuals with multiple myeloma

2. Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma

4. Prognostic and predictive performance of R-ISS with SKY92 in older patients with multiple myeloma: the HOVON-87/NMSG-18 trial

5. P804: PLASMA CELL LEUKEMIA-LIKE TRANSCRIPTOME OF BONE MARROW PLASMA CELLS AND CIRCULATING TUMOR CELL LEVELS IN PERIPHERAL BLOOD COMPLEMENTARILY DEFINE HIGH-RISK IN NEWLY DIAGNOSED MULTIPLE MYELOMA

6. P872: EFFICACY OF DARATUMUMAB PLUS BORTEZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA PRESENTING WITH EXTRAMEDULLARY DISEASE: A EUROPEAN MYELOMA NETWORK STUDY (EMN19)

8. Author Correction: Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma

9. Supplementary Table 3 from A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma

11. Supplementary Table 4 from A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma

12. Supplementary Figures from A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma

13. Supplementary Table 2 from A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma

14. Supplementary Table 1 from A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma

15. An IL-1β driven neutrophil-stromal cell axis fosters a BAFF-rich microenvironment in multiple myeloma

18. Transcriptome-wide association study of multiple myeloma identifies candidate susceptibility genes

19. Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology

20. Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma

21. Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile

22. P-062: MAF translocations are enriched in high-risk NDMM patients with elevated levels of circulating tumor cells suggesting a genetic basis for the aggressive disease course

23. OAB-029: Single-cell transcriptomic analysis reveals reduction of cytotoxic NK cells in a subset of newly diagnosed multiple myeloma patients impacting outcome after daratumumab therapy

24. P-082: Stromal cell - neutrophil interactions are driving a pro tumor environment in multiple myeloma

25. Treatment emergent peripheral neuropathy in the CASSIOPEIA trial

26. Molecular Signature of 18F-FDG PET Biomarkers in Newly Diagnosed Multiple Myeloma Patients: A Genome-Wide Transcriptome Analysis from the CASSIOPET Study

31. Molecular signature of FDG-PET biomarkers in newly diagnosed multiple myeloma patients: a genomewide transcriptome analysis from the CASSIOPET study.

34. V-Domain Ig Suppressor of T Cell Activation (VISTA) Expression Is an Independent Prognostic Factor in Multiple Myeloma

36. Molecular signature of FDG-PET biomarkers in newly diagnosed multiple myeloma patients: a genome-wide transcriptome analysis from the CASSIOPET study.

37. VS38c and CD38-Multiepitope Antibodies Provide Highly Comparable Minimal Residual Disease Data in Patients With Multiple Myeloma.

39. Search for multiple myeloma risk factors using Mendelian randomization

40. Preclinical evaluation of the new GPRC5DxCD3 (JNJ-7564) bispecific antibody for the treatment of multiple myeloma

41. Prognostic and Predictive Performance of SKY92 Combined with R-ISS in Elderly Multiple Myeloma Patients in The Hovon-87/NMSG-18 Study

43. Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology

45. Transcriptomics in Multiple Myeloma Demonstrates an Association between Survival and Expression of T Cell Co-Signaling Ligands in Bone Marrow Derived Myeloma Plasma Cells

46. Differential Effect of Upfront Intensification Treatment in Genetically Defined Myeloma Risk Groups - a Combined Analysis of ISS, Del17p and SKY92 Scores in the EMN-02/HOVON-95 MM Trial

47. Cancer-selective targeting of the NF-?B survival pathway with GADD45ß/MKK7 inhibitors

48. A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis

50. A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Multiple Myeloma Patients

Catalog

Books, media, physical & digital resources